We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+1.77%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.85B
AUM Growth
+$217M
Cap. Flow
+$578M
Cap. Flow %
8.44%
Top 10 Hldgs %
38.32%
Holding
136
New
16
Increased
27
Reduced
15
Closed
11

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$112M
2
APLS
Apellis Pharmaceuticals
APLS
+$78.4M
3
PEN icon
Penumbra
PEN
+$62.3M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$54.4M
5
ARGX icon
argenx
ARGX
+$53.9M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$153M
2
INMD icon
InMode
INMD
+$19.9M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$17.3M
4
AGEN
Agenus
AGEN
+$12.9M
5
GH icon
Guardant Health
GH
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.33%
2 Financials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASLN
101
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$3.64M 0.05%
81,250
– –
ISO
102
DELISTED
IsoPlexis Corporation Common Stock
ISO
$3.35M 0.05%
+365,000
New +$4.05M
MSAC
103
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$2.91M 0.04%
300,000
– –
MXCT icon
104
MaxCyte
MXCT
$126M
$2.8M 0.04%
275,000
– –
PNT
105
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$2.74M 0.04%
490,000
– –
CNTB
106
Connect Biopharma Holdings
CNTB
$139M
$2.32M 0.03%
450,000
– –
APEN
107
DELISTED
Apollo Endosurgery, Inc.
APEN
$2.17M 0.03%
+258,064
New +$2.25M
TBIO
108
DELISTED
Telesis Bio, Inc. Common Stock
TBIO
$2.16M 0.03%
11,111
– –
TNGX icon
109
Tango Therapeutics
TNGX
$4.41B
$1.98M 0.03%
180,819
-419,181
-70% -$5.04M
INKT icon
110
MiNK Therapeutics
INKT
$54.6M
$1.86M 0.03%
+41,667
New +$4.95M
MDXG icon
111
MiMedx Group
MDXG
$633M
$1.79M 0.03%
295,748
– –
WGS icon
112
GeneDx Holdings
WGS
$2.3B
$1.78M 0.03%
12,121
– –
RXST icon
113
RxSight
RXST
$260M
$1.69M 0.02%
150,000
– –
AKYA
114
DELISTED
Akoya BioSciences
AKYA
$1.53M 0.02%
100,000
– –
MIRO
115
DELISTED
Miromatrix Medical Inc. Common Stock
MIRO
$1.31M 0.02%
280,000
– –
RCEL icon
116
Avita Medical
RCEL
$240M
$1.28M 0.02%
106,667
-173,333
-62% -$2.64M
OMIC
117
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$1.16M 0.02%
3,333
– –
MASS icon
118
908 Devices
MASS
$364M
$1.03M 0.02%
40,000
– –
UTRS
119
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
$853K 0.01%
+8,300
New +$1.18M
BOLT icon
120
Bolt Biotherapeutics
BOLT
$7.78M
$619K 0.01%
6,318
– –
ZY
121
DELISTED
Zymergen Inc. Common Stock
ZY
$468K 0.01%
70,000
– –
RCOR.WS
122
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
$200K ﹤0.01%
350,000
– –
ACHL
123
DELISTED
Achilles Therapeutics
ACHL
$61K ﹤0.01%
+12,229
New +$74K
MSACW
124
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$24K ﹤0.01%
33,331
– –
APVO icon
125
Aptevo Therapeutics
APVO
$5.21M
– –
0
– -$4.34M
2 3 4
5
6

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q4 2021 Portfolio in Review

As of Q4 2021, RTW Investments held 136 positions worth $6.85B, up 3.3% from $6.63B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

RTW Investments deployed $578M of net new capital in Q4 2021, opening 16 new positions and adding to 27 existing holdings. Its largest new stake was Ultragenyx Pharmaceutical: 1,373,284 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was IDEAYA Biosciences, an estimated $17.3M trimmed.

  • RTW Investments's largest Q4 2021 buy was Ultragenyx Pharmaceutical: 1,373,284 shares worth $115M.
  • RTW Investments added most to Penumbra in Q4 2021, an estimated $62.3M increase.
  • RTW Investments's biggest Q4 2021 reduction was IDEAYA Biosciences, cutting an estimated $17.3M.
  • RTW Investments fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $153M.
  • RTW Investments's ten largest holdings make up 38% of its $6.85B portfolio in Q4 2021.
  • RTW Investments opened 16 new positions and closed 11 in Q4 2021.
  • RTW Investments's portfolio value rose 3.3% quarter-over-quarter to $6.85B.

Based on RTW Investments's 13F filing for Q4 2021, filed 14 Feb 2022.